

Caterina Chessa

📍 **Work:** P.O. San Francesco, via Mannironi n°1 Nuoro (NU), Italy

Date of birth: 20/06/1997

EDUCATION & TRAINING

[04/10/2017 - 12/07/2023]

Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia

Università degli Studi di Cagliari

City: Cagliari | **Country:** Italy | **Field(s) of study:** Medicine | **Level in EQF:** 7 | **Thesis:** Retrospective Single-Center Cohort Analysis of Patients Affected by Follicular Lymphoma: Long-Term Outcome and Clinical Impact

[01/11/2023 - Current]

Diploma di Scuola di Specializzazione Medica in Ematologia

Università degli Studi di Cagliari

Address: P.O. Oncologico "A. Businco", A.R.N.A.S. Brotzu Via Jenner snc, Cagliari (Italy) | **Field(s) of study:** Medicine | **Level in EQF:** 8

WORK EXPERIENCE

Dirigente Medico Specializzando in Ematologia

City: Nuoro | **Country:** Italy | **Name of unit or department:** Struttura Complessa di Ematologia e C.T.M.O. | **Business/sector:** Human health and social work activities

[04/05/2026 - Current]

Specialised doctor

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English

LISTENING: B1 **READING:** B2 **WRITING:** B1

SPOKEN PRODUCTION: B1 **SPOKEN INTERACTION:** B1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user

PUBLICATIONS

[2024]

[Incidence of Atrial Fibrillation \(AF\) in Chronic Lymphocytic Leukemia \(CLL\) Patients: A Real-World Retrospective Comparison of Ibrutinib and Acalabrutinib](#)

Authors: Roberta Murru, Idanna Innocenti, Andrea Galitzia, Annamaria Tomasso, Caterina Chessa, Marco Murineddu, Alberto Fresa, Valeria Oggianu, Francesco Autore, Antonio Mosca, Giovanni Caocci, Angelo D. Palmas, Giorgio La Nasa, Luca Laurenti | **Volume, Issue and Pages:** Blood (2024) 144 (Supplement 1): 6779

[2025]

[Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by er](#)

Authors: Thomas Chatzikonstantinou et al. | **Volume, Issue and Pages:** Blood, Volume 146, Supplement 1, 3 November 2025, Page 5665

[2025]

[Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki](#)

Authors: Luca Laurenti et al. | **Volume, Issue and Pages:** Blood (2025) 146 (Supplement 1): 7

[2025] [Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.](#)

Authors: Thomas Chatzikonstantinou et al. | **Volume, Issue and Pages:** Blood (2025) 146 (Supplement 1): 5664.

[2025] [Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.](#)

Authors: Thomas Chatzikonstantinou et al. | **Volume, Issue and Pages:** Blood (2025) 146 (Supplement 1): 2120.